AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas.

Bunse, Lukas; Rupp, Anne-Kathleen; Poschke, Isabel; Bunse, Theresa; Lindner, Katharina; Wick, Antje; Blobner, Jens; Misch, Martin; Tabatabai, Ghazaleh; Glas, Martin; Schnell, Oliver; Gempt, Jens; Denk, Monika; Reifenberger, Guido; Bendszus, Martin; Wuchter, Patrick; Steinbach, Joachim P; Wick, Wolfgang; Platten, Michael

Bunse, Lukas; Rupp, Anne-Kathleen; Poschke, Isabel; Bunse, Theresa; Lindner, Katharina; Wick, Antje; Blobner, Jens; Misch, Martin; Tabatabai, Ghazaleh; Glas, Martin; Schnell, Oliver; Gempt, Jens; Denk, Monika; Reifenberger, Guido; Bendszus, Martin; Wuchter, Patrick; Steinbach, Joachim P; Wick, Wolfgang; Platten, Michael.

Bunse L; DKTK (German Cancer Consortium) Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Rupp AK; Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany.
Poschke I; National Center for Tumor Diseases (NCT) Trial Center, NCT, Heidelberg, Germany.
Bunse T; DKTK (German Cancer Consortium) Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Lindner K; Immune Monitoring Unit, NCT, Heidelberg, Germany.
Wick A; DKTK (German Cancer Consortium) Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Blobner J; Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany.
Misch M; DKTK (German Cancer Consortium) Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Tabatabai G; Faculty of Biosciences, University Heidelberg, Heidelberg, Germany.
Glas M; Neurology Clinic, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany.
Schnell O; NCT, Heidelberg, Germany.
Gempt J; Department of Neurosurgery, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany.
Denk M; Department of Neurosurgery, Charité Medical Center, University of Berlin, Berlin, Germany.
Reifenberger G; Department of Neurology and Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, DKTK, DKFZ Partner Site, Eberhard Karls University Tübingen, Tübingen, Germany.
Bendszus M; Division of Clinical Neurooncology, Department of Neurology and (DKTK) Partner Site, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Wuchter P; Department of Neurosurgery, University Hospital Freiburg, Freiburg, Germany.
Steinbach JP; Department of Neurosurgery, Klinikum Rechts Der Isar, School of Medicine, Technical University Munich, Munich, Germany.
Wick W; Institute of Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.
Platten M; Institute of Neuropathology, Heinrich Heine University Düsseldorf, Medical Faculty, University Hospital Düsseldorf, Düsseldorf, Germany.

Neurol Res Pract ; 4(1): 20, 2022 May 23.

Article en En | MEDLINE | ID: mdl-35599302

Palabras clave

Astrocytoma; Avelumab; Brain tumors; Immune checkpoint inhibition; Isocitrate dehydrogenase 1; Oligodendroglioma; Peptide vaccine; Recurrent glioma; T cell receptor sequencing; Window-of-opportunity

Texto completo

Imprimir

XML

PubMed Links

Search on Google